Glucose-lowering therapy after myocardial infarction: more questions than answers.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 18199566.
- Also identified by DOI 10.1093/eurheartj/ehm595.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This editorial refers to The impact of glucose-lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial by L.G. Mellbin et al., on page 166 and Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart by M. Alselmino et al., on page 177
Medical subject headings
- Diabetes Mellitus, Type 2
- Diabetic Angiopathies
- Hypoglycemic Agents
- Myocardial Infarction